Within this multi-disciplinary Program Project (PP) directed toward the discovery of novel physiologically important peptide ligands and toward expanding our understanding of the mechanisms of action of peptide conotoxins, the "Characterization and Synthesis of Novel Conotoxin Peptides" Core B has multiple aims (described below) that result in it being subservient directly or indirectly to all Projects. Additionally, it will contribute reagents to the broader scientific community. This Core will carry out several critical and distinct activities consisting of peptide synthesis, purification, analysis and characterization, mass spectrometric analysis of synthetic and native peptides, development of methodologies as required by synthetic and analytical challenges and discovery projects all outlined under Specific Aims (1-5). Peptide synthesis will be done using the Boc or Fmoc strategies on solid supports, at room and elevated temperatures. Peptide analysis and characterization will use high performance liquid chromatography (HPLC), capillary zone electrophoresis (CZE), circular dichroism (CD) and mass spectromety (MS). Methodological developments may include the synthesis of posttranslational novel amino acids or the testing of novel supports for chromatography among others. Mass spectrometry will be used independently to follow native conotoxins through their purification steps carried out at the University of Utah (ca. 1000 runs/year) and characterization of synthetic peptides at the Salk Institute (ca. 500 runs/year). Discovery projects will concentrate on the design of analogs of selected toxins using original SAR approaches developed over many years at Salk. For each of these services, highly specialized equipment and well-trained personnel are essential and available. To include these into each of the Projects would lead to a duplication of effort and thus be inefficient. In contrast, by centralizing these efforts in a Core, productivity can be increased through specialization. Quality control can also be more consistently and efficiently supervised by the Core Directors. The Core will be administered jointly by Drs. J. Rivier, B. Olivera, M. McIntosh and W. Fischer. Priorities will be assigned in consultation with the users as defined in the application. In general, a first come, first served policy will be used to assign priority.

Public Health Relevance

Within the multi-disciplinary goals of this Program Project directed toward the isolation (from Conus venoms), chemical and biological characterization of novel conotoxins, Core B provides the tools and challenging expertise needed for the total synthesis of significant amounts of well-characterized synthetic replicates. These reagents are used by members of the program projects and collaborators worldwide thus contributing significantly to both basic and applied research otherwise impossible when commercial supplies are both limited and outrageously (but justifiably) expensive (often more than $1,000 per milligram).

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Program Projects (P01)
Project #
2P01GM048677-21A1
Application #
8740924
Study Section
Special Emphasis Panel (ZRG1-MDCN-G (40))
Project Start
Project End
Budget Start
2014-09-10
Budget End
2015-07-31
Support Year
21
Fiscal Year
2014
Total Cost
$233,623
Indirect Cost
Name
University of Utah
Department
Type
DUNS #
009095365
City
Salt Lake City
State
UT
Country
United States
Zip Code
84112
Engle, Staci E; McIntosh, J Michael; Drenan, Ryan M (2015) Nicotine and ethanol cooperate to enhance ventral tegmental area AMPA receptor function via ?6-containing nicotinic receptors. Neuropharmacology 91:13-22
Olivera, Baldomero M; Showers Corneli, Patrice; Watkins, Maren et al. (2014) Biodiversity of cone snails and other venomous marine gastropods: evolutionary success through neuropharmacology. Annu Rev Anim Biosci 2:487-513
Marks, Michael J; Grady, Sharon R; Salminen, Outi et al. (2014) ?6?2*-subtype nicotinic acetylcholine receptors are more sensitive than ?4?2*-subtype receptors to regulation by chronic nicotine administration. J Neurochem 130:185-98
Di Cesare Mannelli, Lorenzo; Cinci, Lorenzo; Micheli, Laura et al. (2014) ?-conotoxin RgIA protects against the development of nerve injury-induced chronic pain and prevents both neuronal and glial derangement. Pain 155:1986-95
Teichert, Russell W; Memon, Tosifa; Aman, Joseph W et al. (2014) Using constellation pharmacology to define comprehensively a somatosensory neuronal subclass. Proc Natl Acad Sci U S A 111:2319-24
Imperial, Julita S; Cabang, April B; Song, Jie et al. (2014) A family of excitatory peptide toxins from venomous crassispirine snails: using Constellation Pharmacology to assess bioactivity. Toxicon 89:45-54
Muldoon, P P; Jackson, K J; Perez, E et al. (2014) The ?3?4* nicotinic ACh receptor subtype mediates physical dependence to morphine: mouse and human studies. Br J Pharmacol 171:3845-57
Chang, Yi-Pin; Banerjee, Jayati; Dowell, Cheryl et al. (2014) Discovery of a potent and selective ?3?4 nicotinic acetylcholine receptor antagonist from an ?-conotoxin synthetic combinatorial library. J Med Chem 57:3511-21
Luo, Sulan; Zhangsun, Dongting; Schroeder, Christina I et al. (2014) A novel ?4/7-conotoxin LvIA from Conus lividus that selectively blocks ?3?2 vs. ?6/?3?2?3 nicotinic acetylcholine receptors. FASEB J 28:1842-53
Hernández-Vivanco, Alicia; Hone, Arik J; Scadden, Mick L et al. (2014) Monkey adrenal chromaffin cells express ?6?4* nicotinic acetylcholine receptors. PLoS One 9:e94142

Showing the most recent 10 out of 171 publications